NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis $5.76 +0.32 (+5.88%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Outlook Therapeutics Stock (NASDAQ:OTLK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Outlook Therapeutics alerts:Sign Up Key Stats Today's Range$5.51▼$5.8450-Day Range$4.94▼$8.0152-Week Range$4.61▼$13.32Volume286,202 shsAverage Volume352,787 shsMarket Capitalization$136.28 millionP/E RatioN/ADividend YieldN/APrice Target$48.20Consensus RatingBuy Company OverviewOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Outlook Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreOTLK MarketRank™: Outlook Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 797th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOutlook Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Outlook Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($3.63) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Outlook Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.63% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.63% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.35 News SentimentOutlook Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Outlook Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 22 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,450.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions.Read more about Outlook Therapeutics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Stock News HeadlinesOutlook Therapeutics, Inc. (NASDAQ:OTLK) CFO Purchases $28,450.00 in StockOctober 1, 2024 | insidertrades.comPositive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity ProgramOctober 25, 2024 | markets.businessinsider.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 29, 2024 | Timothy Sykes (Ad)Outlook Therapeutics' (OTLK) "Buy" Rating Reaffirmed at BTIG ResearchOctober 20, 2024 | americanbankingnews.comOutlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry ShiftsOctober 19, 2024 | markets.businessinsider.comOutlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentOctober 17, 2024 | finance.yahoo.comEconomic Outlook Conference will “Re-Imagine” the future of the Ohio ValleyOctober 12, 2024 | msn.comOutlook down? Microsoft confirms issues with email service, but a fix is now hereOctober 12, 2024 | yahoo.comSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Outlook Therapeutics' stock was trading at $7.88 at the start of the year. Since then, OTLK stock has decreased by 26.9% and is now trading at $5.76. View the best growth stocks for 2024 here. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its earnings results on Wednesday, August, 14th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.23. When did Outlook Therapeutics' stock split? Outlook Therapeutics shares reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Outlook Therapeutics' major shareholders? Top institutional investors of Outlook Therapeutics include Christensen King & Associates Investment Services Inc. (0.04%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon, Yezan Munther Haddadin, C Russell Trenary III and Ghiath M Sukhtian. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Outlook Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2024Today10/29/2024Next Earnings (Estimated)12/27/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$48.20 High Stock Price Target$100.00 Low Stock Price Target$30.00 Potential Upside/Downside+736.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($10.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-160.88% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-5.19Miscellaneous Outstanding Shares23,660,000Free Float22,852,000Market Cap$136.28 million OptionableOptionable Beta0.62 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:OTLK) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.